INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.15
-0.41 (-2.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close14.56
Open14.56
Bid7.50 x 900
Ask16.20 x 2200
Day's range14.11 - 14.60
52-week range11.47 - 17.99
Volume810,114
Avg. volume934,828
Market cap1.436B
Beta1.42
PE ratio (TTM)10.96
EPS (TTM)1.29
Earnings date24 Jul 2018 - 30 Jul 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend date2015-09-08
1y target est15.33
Trade prices are not sourced from all markets
  • 3 Top Healthcare Stocks to Buy in June
    Motley Fool8 days ago

    3 Top Healthcare Stocks to Buy in June

    These three mid-cap healthcare stocks could be your prescription for profits.

  • The Cheapest Drug Stocks to Buy Right Now
    Motley Fool12 days ago

    The Cheapest Drug Stocks to Buy Right Now

    All three of these bargains have forward P/E ratios of less than eight.

  • Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
    Zacks24 days ago

    Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

    Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

  • Business Wire26 days ago

    GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease .

  • Business Wirelast month

    Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer

    Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.

  • GlobeNewswire2 months ago

    Research Report Identifies ILG, Innoviva, iRobot, KBR, KapStone Paper and Packaging, and Lumentum with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ILG ...

  • Associated Press2 months ago

    Innoviva: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 35 cents per share. The biopharmaceutical ...

  • Business Wire2 months ago

    Innoviva Reports First Quarter 2018 Financial Results

    Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2018.

  • Business Wire2 months ago

    Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients With COPD

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which means Trelegy Ellipta can now be used by US physicians to treat a broader population of chronic obstructive pulmonary disease (COPD) patients with airflow limitation or who have experienced an acute worsening of respiratory symptoms. The new indication is for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.

  • Business Wire2 months ago

    Landmark IMPACT Study Published in NEJM Shows Significant Benefits of Trelegy Ellipta for Patients with COPD

    A significant reduction in the risk of on-treatment all-cause mortality was observed for both inhaled corticosteroid containing arms compared to Anoro. Dave Allen, Head, Respiratory Therapy Area R&D, GSK, said, “Reducing exacerbations to keep patients out of hospital is a key goal of COPD management alongside improving lung function and quality of life. The IMPACT study shows how Trelegy Ellipta can help patients with a history of exacerbation achieve these goals.

  • Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta
    Investor's Business Daily3 months ago

    Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

    GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base.  The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...

  • Business Wire4 months ago

    GSK Announces Positive EU Approval for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.

  • New Strong Sell Stocks for February 21st
    Zacks4 months ago

    New Strong Sell Stocks for February 21st

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • Business Wire4 months ago

    GSK Submits Landmark IMPACT Data to European Medicines Agency to Support Expanded Label for Trelegy Ellipta

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease .

  • Why Innoviva Inc. Stock Jumped Tuesday
    Motley Fool4 months ago

    Why Innoviva Inc. Stock Jumped Tuesday

    An activist hedge fund is shaking things up at Innoviva.

  • PR Newswire4 months ago

    Sarissa Capital Reconstitutes Innoviva Board Of Directors

    Follows Termination of CEO Mike Aguiar GREENWICH, Conn. , Feb. 13, 2018 /PRNewswire/ -- Sarissa Capital Management LP announced today that Sarissa Capital has entered into an agreement with Innoviva, Inc. ...

  • Associated Press4 months ago

    Innoviva beats Street 4Q forecasts

    The Brisbane, California-based company said it had profit of 45 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...

  • Business Wire4 months ago

    Innoviva Reports Record Fourth Quarter and Full Year 2017 Financial Results

    Innoviva, Inc. today reported financial results for the fourth quarter and full year 2017. Gross royalties earned on net sales of RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA® from Glaxo Group Limited during the fourth quarter of 2017 were $70.5 million, up 51% from $46.8 million in the fourth quarter of 2016.

  • Business Wire5 months ago

    Innoviva to Report Fourth Quarter Financial Results on February 8 at 5:00 p.m. EDT

    Innoviva, Inc. announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017. Following the earnings release, Innoviva management will host a webcast and conference call at 5:00 p.m.

  • Business Wire5 months ago

    GSK Announces CHMP Positive Opinion for Labelling Update to Relvar Ellipta in Patients with Asthma

    GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting ...

  • Innoviva Sees RS Rating Rise To 74
    Investor's Business Daily6 months ago

    Innoviva Sees RS Rating Rise To 74

    A Relative Strength Rating upgrade for Innoviva shows improving technical performance. Will it continue?

  • Innoviva Earns Relative Strength Rating Upgrade
    Investor's Business Daily6 months ago

    Innoviva Earns Relative Strength Rating Upgrade

    Innoviva shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

  • Business Wire6 months ago

    Innoviva and Sarissa Implement Court Order

    Innoviva, Inc. today announced it implemented the Delaware Court of Chancery’s order enforcing the oral settlement agreement with Sarissa Capital Domestic Fund LP and certain of its affiliates in connection with the Company’s 2017 annual meeting of stockholders, held on April 20, 2017.

  • Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler
    Zacks7 months ago

    Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler

    Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.